Current evidence for moderate and ultra-hypofractionated radiation therapy in prostate cancer: a summary of the results from phase 3 randomised trials
DOI:
https://doi.org/10.2340/sju.v58.7719Keywords:
prostate cancer, moderate hypofractionated, ultrahypofractionated, radiation therapyAbstract
Problem: A low α/β ratio for prostate cancer (PCa) compared to surrounding normal tissue theoretically implies therapeutical advantages with hypofractionated treatment. Data from large randomised control trials (RCTs) comparing moderate hypofractionated (MHRT, 2.4–3.4 Gray/fraction (Gy/fx)) and ultra-hypofractionated (UHRT, >5 Gy/fx) with conventionally fractionated radiation therapy (CFRT, 1.8–2 Gy/fx) and the possible clinical implications have been reviewed.
Materials and method: We searched PubMed, Cochrane and Scopus for RCT comparing MHRT/UHRT with CFRT treatment of locally and/or locally advanced (N0M0) PCa. We found six RCTs, which compared different radiation therapy regimes. Tumour control and acute and late toxicities are reported.
Results: MHRT was non-inferior to CFRT for intermediate-risk PCa, non-inferior for low-risk PCa and not superior in terms of tumour control for high-risk PCa. Acute toxicity rates were increased compared to CFRT, especially an increase in acute gastrointestinal adverse effects was seen. Late toxicity related to MHRT seems to be comparable. UHRT was non-inferior in terms of tumour control in one RCT, with increased acute toxicity, but with comparable late toxicity. One trial, however, indicated increased late toxicity rates with UHRT.
Discussion and conclusion: MHRT delivers similar therapeutic outcomes compared to CFRT in terms of tumour control and late toxicity for intermediate-risk PCa patients. Slightly more acute transient toxicity could be tolerated in favour of a shorter treatment course. UHRT should be regarded as an optional treatment for patients with low- and intermediate-risk disease applied at experienced centres in concordance with international and national guidelines.
Downloads
References
Larønningen S, Ferlay J, Beydogan H, et al. NORDCAN: Cancer incidence, mortality, prevalence and survival in the Nordic countries [Internet]; 2022 [cited 24-04-2023]. Version 9.2 (23.06.2022). Association of the Nordic Cancer Registries. Cancer Registry of Norway. Available from: https://nordcan.iarc.fr/
Hamdy FC, Donovan JL, Lane JA, et al. 10-Year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer. N Engl J Med. 2016 Oct 13;375(15):1415–24. https://doi.org/10.1056/NEJMoa1606220 DOI: https://doi.org/10.1056/NEJMoa1606220
Warde P, Mason M, Ding K, et al. Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial. Lancet. 2011 Dec 17;378(9809):2104–11. https://doi.org/10.1016/S0140-6736(11)61095-7 DOI: https://doi.org/10.1016/S0140-6736(11)61095-7
Widmark A, Klepp O, Solberg A, et al. Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial. Lancet. 2009 Jan 24;373(9660):301–8. https://doi.org/10.1016/S0140-6736(08)61815-2 DOI: https://doi.org/10.1016/S0140-6736(08)61815-2
Årsrapport 2020 med resultater og forbedringstiltak fra Nasjonalt kvalitetsregister for prostatakreft [Internet]; 2021 [cited 24-04-2023]. Oslo: Kreftregisteret. Available from: https://www.kreftregisteret.no/globalassets/publikasjoner-og-rapporter/arsrapporter/publisert-2021/arsrapport-nasjonalt-kvalitetsregister-for-prostatakreft-2020.pdf
Nationella prostatacancerregistret. The National Prostate Cancer Register of Sweden and Prostate Cancer data Base Sweden 2.0 [internet]. 2023 [cited 2023 Apr 24]. Available from: https://npcr.se/wp-content/uploads/2021/09/20210901_npcr_nationell_rapport_2020.pdf
Dansk Prostata Cancer Database. Årsrapport 2020. Juli 2021 Regionernes Kliniske Kvalitetsudviklingsprogram [Internet]. 2023. Available from: https://ducg.dk/fileadmin/ingen_mappe_valgt/daproca_aarsrapport_2020_offentlig.pdf
Wang JZ, Li XA, Yu CX, et al. The low alpha/beta ratio for prostate cancer: what does the clinical outcome of HDR brachytherapy tell us? Int J Radiat Oncol Biol Phys. 2003 Nov 15;57(4):1101–8. https://doi.org/10.1016/S0360-3016(03)00747-8 DOI: https://doi.org/10.1016/S0360-3016(03)00747-8
Benjamin LC, Tree AC, Dearnaley DP. The role of hypofractionated radiotherapy in prostate cancer. Curr Oncol Rep. 2017 Apr;19(4):30. https://doi.org/10.1007/s11912-017-0584-7 DOI: https://doi.org/10.1007/s11912-017-0584-7
Brenner DJ, Hall EJ. Fractionation and protraction for radiotherapy of prostate carcinoma. Int J Radiat Oncol Biol Phys. 1999 Mar 15;43(5):1095–101. https://doi.org/10.1016/S0360-3016(98)00438-6 DOI: https://doi.org/10.1016/S0360-3016(98)00438-6
Morgan SC, Hoffman K, Loblaw DA, et al. Hypofractionated radiation therapy for localized prostate cancer: executive summary of an ASTRO, ASCO and AUA evidence-based guideline. J Urol. 2019 Mar;201(3):528–34. https://doi.org/10.1097/JU.0000000000000071 DOI: https://doi.org/10.1097/JU.0000000000000071
Mottet N, Cornford P, van den Bergh RCN, et al. EAU-EANM- ESTRO- ESUR- ISUP - SIOG- Guidelines on Prostate Cancer [Internet]. 2013 [cited 24-04-2023]. Arnhem, the Netherlands: EAU Guidelines Office. Available from: https://d56bochluxqnz.cloudfront.net/documents/full-guideline/EAU-EANM-ESTRO-ESUR-ISUP-SIOG-Guidelines-on-Prostate-Cancer-2023_2023-03-27-131655_pdvy.pdf
Wolf F, Sedlmayer F, Aebersold D, et al. Ultrahypofractionation of localized prostate cancer: statement from the DEGRO working group prostate cancer. Strahlenther Onkol. 2021 Feb;197(2):89–96. https://doi.org/10.1007/s00066-020-01723-8 DOI: https://doi.org/10.1007/s00066-020-01723-8
Datta NR, Stutz E, Rogers S, et al. Conventional versus hypofractionated radiation therapy for localized or locally advanced prostate cancer: a systematic review and meta-analysis along with therapeutic implications. Int J Radiat Oncol Biol Phys. 2017 Nov 1;99(3):573–89. https://doi.org/10.1016/j.ijrobp.2017.07.021 DOI: https://doi.org/10.1016/j.ijrobp.2017.07.021
Jackson WC, Silva J, Hartman HE, et al. Stereotactic body radiation therapy for localized prostate cancer: a systematic review and meta-analysis of over 6,000 patients treated on prospective studies. Int J Radiat Oncol Biol Phys. 2019 Jul 15;104(4):778–89. https://doi.org/10.1016/j.ijrobp.2019.03.051 DOI: https://doi.org/10.1016/j.ijrobp.2019.03.051
Lee WR, Dignam JJ, Amin MB, et al. Randomized phase III noninferiority study comparing two radiotherapy fractionation schedules in patients with low-risk prostate cancer. J Clin Oncol. 2016 Jul 10;34(20):2325–32. https://doi.org/10.1200/JCO.2016.67.0448 DOI: https://doi.org/10.1200/JCO.2016.67.0448
Dearnaley D, Syndikus I, Mossop H, et al. Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial. Lancet Oncol. 2016 Aug;17(8):1047–60. https://doi.org/10.1016/S1470-2045(16)30102-4 DOI: https://doi.org/10.1016/S1470-2045(16)30102-4
Catton CN, Lukka H, Gu CS, et al. Randomized trial of a hypofractionated radiation regimen for the treatment of localized prostate cancer. J Clin Oncol. 2017 Jun 10;35(17):1884–90. https://doi.org/10.1200/JCO.2016.71.7397 DOI: https://doi.org/10.1200/JCO.2016.71.7397
Incrocci L, Wortel RC, Alemayehu WG, et al. Hypofractionated versus conventionally fractionated radiotherapy for patients with localised prostate cancer (HYPRO): final efficacy results from a randomised, multicentre, open-label, phase 3 trial. Lancet Oncol. 2016 Aug;17(8):1061–9. https://doi.org/10.1016/S1470-2045(16)30070-5 DOI: https://doi.org/10.1016/S1470-2045(16)30070-5
de Vries KC, Wortel RC, Oomen-de Hoop E, et al. Hyprofractionated versus conventionally fractionated radiation therapy for patients with intermediate- or high-risk, localized, prostate cancer: 7-year outcomes from the randomized, multicenter, open-label, phase 3 HYPRO trial. Int J Radiat Oncol Biol Phys. 2020 Jan 1;106(1):108–15. https://doi.org/10.1016/j.ijrobp.2019.09.007 DOI: https://doi.org/10.1016/j.ijrobp.2019.09.007
Aluwini S, Pos F, Schimmel E, et al. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): late toxicity results from a randomised, non-inferiority, phase 3 trial. Lancet Oncol. 2016 Apr;17(4):464–74. https://doi.org/10.1016/S1470-2045(15)00567-7 DOI: https://doi.org/10.1016/S1470-2045(15)00567-7
Aluwini S, Pos F, Schimmel E, et al. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): acute toxicity results from a randomised non-inferiority phase 3 trial. Lancet Oncol. 2015 Mar;16(3):274–83. https://doi.org/10.1016/S1470-2045(14)70482-6 DOI: https://doi.org/10.1016/S1470-2045(14)70482-6
Widmark A, Gunnlaugsson A, Beckman L, et al. Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial. Lancet. 2019 Aug 3;394(10196):385–95. https://doi.org/10.1016/S0140-6736(19)31131-6 DOI: https://doi.org/10.1016/S0140-6736(19)31131-6
Brand DH, Tree AC, Ostler P, et al. Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial. Lancet Oncol. 2019 Nov;20(11):1531–43. https://doi.org/10.1016/S1470-2045(19)30569-8 DOI: https://doi.org/10.1016/S1470-2045(19)30569-8
Tree AC, Ostler P, van der Voet H, et al. Intensity-modulated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): 2-year toxicity results from an open-label, randomised, phase 3, non-inferiority trial. Lancet Oncol. 2022 Oct;23(10):1308–20. https://doi.org/10.1016/S1470-2045(22)00517-4 DOI: https://doi.org/10.1016/S1470-2045(22)00517-4
Staffurth JN, Haviland JS, Wilkins A, et al. Impact of hypofractionated radiotherapy on patient-reported outcomes in prostate cancer: results up to 5 yr in the CHHiP trial (CRUK/06/016). Eur Urol Oncol. 2021 Dec;4(6):980–92. https://doi.org/10.1016/j.euo.2021.07.005 DOI: https://doi.org/10.1016/j.euo.2021.07.005
Sinzabakira F, Heemsbergen WD, Pos FJ, et al. Patient-reported outcomes in the acute phase of the randomized hypofractionated irradiation for prostate cancer (HYPRO) trial. Int J Radiat Oncol Biol Phys. 2022 Mar 15;112(4):870–9. https://doi.org/10.1016/j.ijrobp.2021.10.139 DOI: https://doi.org/10.1016/j.ijrobp.2021.10.139
Bruner DW, Pugh SL, Lee WR, Hall WA, Dignam JJ, Low D, et al. Quality of life in patients with low-risk prostate cancer treated with hypofractionated vs conventional radiotherapy: a phase 3 randomized clinical trial. JAMA Oncol. 2019;5(5):664–70. https://doi.org/10.1001/jamaoncol.2018.6752 DOI: https://doi.org/10.1001/jamaoncol.2018.6752
Fransson P, Nilsson P, Gunnlaugsson A, et al. Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer (HYPO-RT-PC): patient-reported quality-of-life outcomes of a randomised, controlled, non-inferiority, phase 3 trial. Lancet Oncol. 2021 Feb;22(2):235–45. https://doi.org/10.1016/S1470-2045(20)30581-7 DOI: https://doi.org/10.1016/S1470-2045(20)30581-7
Lukka H, Hayter C, Julian JA, et al. Randomized trial comparing two fractionation schedules for patients with localized prostate cancer. J Clin Oncol. 2005 Sep 1;23(25):6132–8. https://doi.org/10.1200/JCO.2005.06.153 DOI: https://doi.org/10.1200/JCO.2005.06.153
Vogelius IR, Bentzen SM. Meta-analysis of the alpha/beta ratio for prostate cancer in the presence of an overall time factor: bad news, good news, or no news? Int J Radiat Oncol Biol Phys. 2013 Jan 1;85(1):89–94. https://doi.org/10.1016/j.ijrobp.2012.03.004 DOI: https://doi.org/10.1016/j.ijrobp.2012.03.004
Vogelius IR, Bentzen SM. Diminishing returns from ultrahypofractionated radiation therapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2020 Jun 1;107(2):299–304. https://doi.org/10.1016/j.ijrobp.2020.01.010 DOI: https://doi.org/10.1016/j.ijrobp.2020.01.010
Kerkmeijer LGW, Pos FJ, Haustermans K, van der Heide UA. Reply to I. R. Vogelius et al. J Clin Oncol. 2021;39(27):3086–7. https://doi.org/10.1200/JCO.21.00789 DOI: https://doi.org/10.1200/JCO.21.00789
Wilson JM, Dearnaley DP, Syndikus I, et al. The efficacy and safety of conventional and hypofractionated high-dose radiation therapy for prostate cancer in an elderly population: a subgroup analysis of the CHHiP trial. Int J Radiat Oncol Biol Phys. 2018 Apr 1;100(5):1179–89. https://doi.org/10.1016/j.ijrobp.2018.01.016 DOI: https://doi.org/10.1016/j.ijrobp.2018.01.016
Yin Y, Li R, Xu K, et al. Androgen receptor variants mediate DNA repair after prostate cancer irradiation. Cancer Res. 2017 Sep 15;77(18):4745–54. https://doi.org/10.1158/0008-5472.CAN-17-0164 DOI: https://doi.org/10.1158/0008-5472.CAN-17-0164
Boonstra PS, Taylor JM, Smolska-Ciszewska B, et al. Alpha/beta (α/β) ratio for prostate cancer derived from external beam radiotherapy and brachytherapy boost. Br J Radiol. 2016;89(1061):20150957. https://doi.org/10.1259/bjr.20150957 DOI: https://doi.org/10.1259/bjr.20150957
Dearnaley D, Hall E. Prostate cancer and hypofractionation: reflections on recent randomised phase III clinical trial results. Transl Androl Urol. 2017 Feb;6(1):134–6. https://doi.org/10.21037/tau.2017.01.05 DOI: https://doi.org/10.21037/tau.2017.01.05
Bolla M, Maingon P, Carrie C, et al. Short androgen suppression and radiation dose escalation for intermediate- and high-risk localized prostate cancer: results of EORTC trial 22991. J Clin Oncol. 2016 May 20;34(15):1748–56. https://doi.org/10.1200/JCO.2015.64.8055 DOI: https://doi.org/10.1200/JCO.2015.64.8055
Solberg A, Haugen OA, Viset T, et al. Residual prostate cancer in patients treated with endocrine therapy with or without radical radiotherapy: a side study of the SPCG-7 randomized trial. Int J Radiat Oncol Biol Phys. 2011 May 1;80(1):55–61. https://doi.org/10.1016/j.ijrobp.2010.01.072 DOI: https://doi.org/10.1016/j.ijrobp.2010.01.072
Kishan AU, Dang A, Katz AJ, et al. Long-term outcomes of stereotactic body radiotherapy for low-risk and intermediate-risk prostate cancer. JAMA Netw Open. 2019 Feb 1;2(2):e188006. https://doi.org/10.1001/jamanetworkopen.2018.8006 DOI: https://doi.org/10.1001/jamanetworkopen.2018.8006
Murray J, Griffin C, Gulliford S, et al. A randomised assessment of image guided radiotherapy within a phase 3 trial of conventional or hypofractionated high dose intensity modulated radiotherapy for prostate cancer. Radiother Oncol. 2020 Jan;142:62–71. https://doi.org/10.1016/j.radonc.2019.10.017 DOI: https://doi.org/10.1016/j.radonc.2019.10.017
Chism DB, Hanlon AL, Horwitz EM, et al. A comparison of the single and double factor high-risk models for risk assignment of prostate cancer treated with 3D conformal radiotherapy. Int J Radiat Oncol Biol Phys. 2004 Jun 1;59(2):380–5. https://doi.org/10.1016/j.ijrobp.2003.10.059 DOI: https://doi.org/10.1016/j.ijrobp.2003.10.059
Dearnaley DP, Griffin C, Syndikus I, et al. Eight-year outcomes of a phase III randomized trial of conventional versus hypofractionated high-dose intensity modulated radiotherapy for prostate cancer (CRUK/06/016): update from the CHHiP trial. J Clin Oncol. 2020;38(6_Suppl):325. https://doi.org/10.1200/JCO.2020.38.6_suppl.325 DOI: https://doi.org/10.1200/JCO.2020.38.6_suppl.325
Koontz BF, Bossi A, Cozzarini C, et al. A systematic review of hypofractionation for primary management of prostate cancer. Eur Urol. 2015 Oct;68(4):683–91. https://doi.org/10.1016/j.eururo.2014.08.009 DOI: https://doi.org/10.1016/j.eururo.2014.08.009
Stensvold A, Dahl AA, Brennhovd B, et al. Methods for prospective studies of adverse effects as applied to prostate cancer patients treated with surgery or radiotherapy without hormones. Prostate. 2012 May 1;72(6):668–76. https://doi.org/10.1002/pros.21470 DOI: https://doi.org/10.1002/pros.21470
Sveistrup J, af Rosenschöld PM, Deasy JO, et al. Improvement in toxicity in high risk prostate cancer patients treated with image-guided intensity-modulated radiotherapy compared to 3D conformal radiotherapy without daily image guidance. Radiat Oncol. 2014 Feb 4;9:44. https://doi.org/10.1186/1748-717X-9-44 DOI: https://doi.org/10.1186/1748-717X-9-44
Wortel RC, Incrocci L, Pos FJ, et al. Late side effects after image guided intensity modulated radiation therapy compared to 3D-conformal radiation therapy for prostate cancer: results from 2 prospective cohorts. Int J Radiat Oncol Biol Phys. 2016 Jun 1;95(2):680–9. https://doi.org/10.1016/j.ijrobp.2016.01.031 DOI: https://doi.org/10.1016/j.ijrobp.2016.01.031
Brand DH, Brüningk SC, Wilkins A, et al. Genitourinary α/β ratios in the CHHiP trial the fraction size sensitivity of late genitourinary toxicity: analysis of alpha/beta (α/β) ratios in the CHHiP trial. Int J Radiat Oncol Biol Phys. 2023;115(2):327–36. https://doi.org/10.1016/j.ijrobp.2022.08.030 DOI: https://doi.org/10.1016/j.ijrobp.2022.08.030
Helsedirektoratet. Om Helsedirektoratets normerende produkter [Internet]. 2023 [cited 24-04-2023]. Oslo: Helsedirektoratet. Available from: https://www.helsedirektoratet.no/retningslinjer/prostatakreft-handlingsprogram
Kunskapsbanken [Internet]; 2022 [cited 24-04-2023]. National prostate cancer guidelines (In Swedish). Version 7.0. The Confederation of Regional Cancer Centres (RCC). Available from: https://kunskapsbanken.cancercentrum.se/globalassets/cancerdiagnoser/prostatacancer/vardprogram/nvp-prostatacancer.pdf
Hamdy FC, Donovan JL, Lane JA, et al. Active monitoring, radical prostatectomy and radical radiotherapy in PSA-detected clinically localised prostate cancer: the ProtecT three-arm RCT. Health Technol Assess. 2020 Aug;24(37):1–176. https://doi.org/10.3310/hta24370 DOI: https://doi.org/10.3310/hta24370
Teramoto S, Ota T, Itaya N, et al. [Survey of factors underlying treatment choice for patients with localized prostate cancer (radical prostatectomy vs extrabeam radiotherapy)]. Nihon Hinyokika Gakkai Zasshi. 2006 Nov;97(7):823–9. https://doi.org/10.5980/jpnjurol1989.97.823 DOI: https://doi.org/10.5980/jpnjurol1989.97.823
Shaverdian N, Verruttipong D, Wang PC, et al. Exploring value from the patient’s perspective between modern radiation therapy modalities for localized prostate cancer. Int J Radiat Oncol Biol Phys. 2017 Mar 1;97(3):516–25. https://doi.org/10.1016/j.ijrobp.2016.11.007 DOI: https://doi.org/10.1016/j.ijrobp.2016.11.007
National Comprehensive Cancer Network [Internet]. 2023 [cited 24-04-2023]. Prostate Cancer (Version 1.2023). Available from: https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1459
Danske Multidiciplinære Cancer Grupper [Internet]. 2023 [cited 24-04-2023]. Klassifikation og stadieinddeling af prostatacancer (Version 2.2). Available from: https://www.dmcg.dk/siteassets/kliniske-retningslinjer---skabeloner-og-vejledninger/kliniske-retningslinjer-opdelt-pa-dmcg/daproca/daproca_klassifikation-og-stadieinddeling_v.2.2_admgodk_16032023.pdf
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Oscar Lilleby, Peter Meidahl Petersen, Gedske Daugaard, Katharina Anne Perell
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Acta Chirurgica Scandinavica Society owns the copyright for all material published until Volume 57 (2023) unless otherwise specified. As from Volume 59 (2024) all published articles, unless otherwise specified, are published under CC-BY licences, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, with the condition of proper attribution to the original work.
